Suppressive activity of RGX-365 on HMGB1-mediated septic responses
DOI:
https://doi.org/10.1590/s2175-97902022e19473%20%20Palavras-chave:
RGX-365, Permeability, HMGB1, SepsisResumo
RGX-365 is the main fraction of black ginseng conmprising protopanaxatriol (PPT)-type rare ginsenosides (ginsenosides Rg4, Rg6, Rh4, Rh1, and Rg2). No studies on the antiseptic activity of RGX-365 have been reported. High mobility group box 1 (HMGB1) is recognized as a late mediator of sepsis, and the inhibition of HMGB1 release and recovery of vascular barrier integrity have emerged as attractive therapeutic strategies for the management of sepsis. In this study, we examined the effects of RGX-365 on HMGB1-mediated septic responses and survival rate in a mouse sepsis model. RGX-365 was administered to the mice after HMGB1 challenge. The antiseptic activity of RGX-365 was assessed based on the production of HMGB1, measurement of permeability, and septic mouse mortality using a cecal ligation and puncture (CLP)-induced sepsis mouse model and HMGB1-activated human umbilical vein endothelial cells (HUVECs). We found that RGX-365 significantly reduced HMGB1 release from LPS- activated HUVECs and CLP-induced release of HMGB1 in mice. RGX-365 also restored HMGB1-mediated vascular disruption and inhibited hyperpermeability in the mice. In addition, treatment with RGX-365 reduced sepsis-related mortality in vivo. Our results suggest that RGX- 365 reduces HMGB1 release and septic mortality in vivo, indicating that it is useful in the treatment of sepsis.
Downloads
Referências
Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000;165(6):2950-2954.
Bae JS. Role of high mobility group box 1 in inflammatory disease: Focus on sepsis. Arch Pharm Res. 2012;35(9):1511-1523.
Bogatcheva NV, Verin AD. The role of cytoskeleton in the regulation of vascular endothelial barrier function. Microvasc Res. 2008;76(3):202-207.
Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov. 2005;4(10):854-865.
Kang OH, Shon MY, Kong R, Seo YS, Zhou T, Kim DY, et al. Anti-diabetic effect of black ginseng extract by augmentation of AMPK protein activity and upregulation of GLUT2 and GLUT4 expression in db/db mice. BMC Complement Altern Med. 2017;17(1):341.
Kim JE, Lee W, Yang S, Cho SH, Baek MC, Song GY, et al. Suppressive effects of rare ginsenosides, Rk1 and Rg5, on HMGB1-mediated septic responses. Food Chem Toxicol. 2019;124:45-53.
Lee IC, Kim DY, Bae JS. Sulforaphane reduces HMGB1- mediated septic responses and improves survival rate in septic mice. Am J Chin Med. 2017a;45(6):1253-1271.
Lee J-H, Cho S-H, Yun M-Y, An S, Jang H-H, Lee SN, et al. Anti-wrinkle effect of rare ginsenosides, produced from ginsenoside Rd. Kor J Aesthet Cosmetol. 2015;13(6):909-916.
Lee W, Ku SK, Kim MA, Bae JS. Anti-factor Xa activities of zingerone with anti-platelet aggregation activity. Food Chem Toxicol . 2017b;105:186-193.
Lee W, Ku SK, Lee YM, Bae JS. Anti-septic effects of glyceollins in HMGB1-induced inflammatory responses in vitro and in vivo. Food Chem Toxicol . 2014;63:1-8.
Lee W, Lee Y, Jeong GS, Ku SK, Bae JS. Cudratricusxanthone A attenuates renal injury in septic mice. Food Chem Toxicol . 2017c;106(Pt A):404-410.
Li Y, Wang F, Luo Y. Ginsenoside Rg1 protects against sepsis- associated encephalopathy through beclin 1-independent autophagy in mice. J Surg Res. 2017;207:181-189.
Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol. 2007;179(1):33-40.
Park JY, Lee DS, Kim CE, Shin MS, Seo CS, Shin HK, et al. Effects of fermented black ginseng on wound healing mediated by angiogenesis through the mitogen-activated protein kinase pathway in human umbilical vein endothelial cells. J Ginseng Res. 2018;42(4):524-531.
Qin YH, Dai SM, Tang GS, Zhang J, Ren D, Wang ZW, et al. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J Immunol . 2009;183(10):6244-6250.
Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. 2003;9(5):517-524.
Russell JA. Management of sepsis. N Engl J Med. 2006;355(16):1699-1713.
Saba E, Lee YY, Kim M, Kim SH, Hong SB, Rhee MH. A comparative study on immune-stimulatory and antioxidant activities of various types of ginseng extracts in murine and rodent models. J Ginseng Res . 2018;42(4):577-584.
Su F, Xue Y, Wang Y, Zhang L, Chen W, Hu S. Protective effect of ginsenosides Rg1 and Re on lipopolysaccharide- induced sepsis by competitive binding to Toll-like receptor 4. Antimicrob Agents Chemother. 2015;59(9):5654-5663.
Sun BS, Gu LJ, Fang ZM, Wang CY, Wang Z, Lee MR, et al. Simultaneous quantification of 19 ginsenosides in black ginseng developed from Panax ginseng by HPLC-ELSD. J Pharm Biomed Anal. 2009a;50(1):15-22.
Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, et al. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen- activated protein kinase pathways. Basic Res Cardiol. 2009b;104(1):42-49.
Walter A, Gutknecht J. Permeability of small nonelectrolytes through lipid bilayer membranes. J Membr Biol. 1986;90(3):207-217.
Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248-251.
Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA. 2004;101(1):296-301.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
Como Citar
Dados de financiamento
-
National Research Foundation
Números do Financiamento 2017R1A5A2015391, 2017R1A5A2015385, 2017R1A2B2005851
